• Biodexa posted a loss attributable to shareholders of GBP 1.84 million in 1H 2026, narrowing from GBP 3.81 million a year earlier.
• R&D costs rose 75% to GBP 2.92 million, driven by higher Serenta trial spending and MTX240 manufacturing costs.
• Administrative costs fell 27% to GBP 1.74 million, primarily due to foreign exchange movements.
• Net cash used in operating activities increased to GBP 4.61 million; cash totaled GBP 3.23 million at June 30, 2026.
• Post-period, it raised USD 3.5 million; Serenta enrolled 92 of 168 subjects, while CEO Stephen Stamp said MTX240 could show efficacy by end-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodexa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609111630PRIMZONEFULLFEED1001262319) on September 11, 2026, and is solely responsible for the information contained therein.